Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen.

OBJECTIVES To investigate whether the second-order kinetics model of prostate-specific antigen (PSA) increase would be more appropriate in some cases than the traditionally assumed first-order model. PSA levels are used to detect tumor recurrence after radical prostatectomy, and the rate of PSA increase is used to predict patients' prognosis. METHODS Sequential PSA values from 147 patients showing detectable PSA after radical prostatectomy were analyzed by nonlinear regression analysis. The best-fitting model was chosen using the lowest sum of squares residual error. RESULTS Of the 147 cases, 90 (61.2%) followed the first-order kinetics, and 57 (38.8%) were better described by second-order kinetics. The order of PSA increase correlated with the Gleason score of the tumor in the radical prostatectomy specimens. The first-order kinetics were associated with tumors with Gleason scores of 5 to 6, 7, and 9, and the second-order kinetics were associated with tumors with a Gleason score of 8 (P < 0.01). Our data did not show a correlation between the order of PSA increase and the clinical prognosis. CONCLUSIONS The presence of a group of tumors in which the increase in PSA follows second-order kinetics is significant. Such an increase may be associated with an autocatalytic mechanism assisting tumor growth. The existence of such a mechanism requires additional investigation.

[1]  J. Xiang,et al.  Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy , 1999, Breast Cancer Research.

[2]  A. D'Amico,et al.  Linear regressive analysis using prostate‐specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer , 1993, Cancer.

[3]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[4]  A Pollack,et al.  The fall and rise of prostate‐specific antigen: Kinetics of serum prostate‐specific antigen levels after radiation therapy for prostate cancer , 1993, Cancer.

[5]  R. Vollmer,et al.  The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[7]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[8]  J. Dekernion,et al.  Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.

[9]  Grégoire Nicolis,et al.  Self-Organization in nonequilibrium systems , 1977 .

[10]  D. Curiel,et al.  Gene therapy for carcinoma of the breast , 2006, Cancer Gene Therapy.

[11]  D. van den Ouden,et al.  Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer. , 1993, British journal of urology.

[12]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[13]  H. Carter,et al.  Natural history of changes in prostate specific antigen in early stage prostate cancer. , 1994, The Journal of urology.

[14]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[15]  On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems. , 2003, American journal of clinical pathology.